BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261022
DTSTAMP:20260620T044539
CREATED:20260617T114733Z
LAST-MODIFIED:20260617T114733Z
UID:43761-1792368000-1792627199@www.pharmajournalist.com
SUMMARY:5th Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:Early Access Programmes have evolved into a critical\, but increasingly complex\, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines\, evidence generation\, and patient access across global markets. \nThe 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift\, reimbursement timelines extend\, and programmes scale globally\, organisations must make more decisions\, earlier\, and with greater consequence. \nThis is the only European forum dedicated to the operational reality of early access – bringing together 140+ leaders across Medical Affairs\, Access\, Regulatory\, Clinical Operations\, and Supply to share how programmes are being designed\, adapted\, and delivered in practice. \nWhether you are building your first programme\, scaling across regions\, or managing a global access portfolio\, this is your opportunity to benchmark your approach\, challenge your assumptions\, and leave with the insight needed to make smarter decisions and deliver earlier\, sustainable access for patients in 2026 and beyond. \nFor more information and to register online\, please click here.
URL:https://www.pharmajournalist.com/event/5th-operationalise-early-access-programmes-summit-europe/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261030
DTSTAMP:20260620T044539
CREATED:20260609T083754Z
LAST-MODIFIED:20260609T083754Z
UID:43704-1792972800-1793318399@www.pharmajournalist.com
SUMMARY:9th TPD & Induced Proximity Summit
DESCRIPTION:After a decade of innovation\, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026\, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already\, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone. \nHowever\, following the risk-averse funding environment of 2025\, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development\, it is designed to help you discover the best novel targets\, optimize your degrader profile\, and accelerate your pipelines to the clinic and beyond. \nView the full event guide.
URL:https://www.pharmajournalist.com/event/9th-tpd-induced-proximity-summit/
LOCATION:The Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR